Literature DB >> 26598976

Undifferentiated Carcinoma of the Endometrium: An Expanded Immunohistochemical Analysis Including PAX-8 and Basal-Like Carcinoma Surrogate Markers.

Preetha Ramalingam1, Ramya P Masand, Elizabeth D Euscher, Anais Malpica.   

Abstract

Undifferentiated carcinoma of the endometrium (UCAe) is an aggressive, underrecognized high-grade carcinoma that can occur either in pure form or in conjunction with low-grade endometrioid adenocarcinoma (i.e. dedifferentiated carcinoma). The typical solid growth pattern of UCAe can create a diagnostic dilemma as it is frequently misinterpreted as the solid component of an endometrial carcinoma or as a sarcoma. In addition, the high nuclear:cytoplasmic ratio, high mitotic index, and geographic necrosis are reminiscent of basal-like carcinoma of breast (BLCB). This study was undertaken to determine the role of a selected group of immunomarkers in the distinction of UCAe from other endometrial carcinomas, and assess the expression of DNA mismatch repair proteins, and surrogate BLCB immunomarkers in this type of tumor. Cases of UCAe were stained with antibodies against keratin cocktail, CK8/18, PAX-8, and estrogen receptor: 35 cases; progesterone receptor and Her-2/neu: 33 cases; CD44, e-cadherin, p16, and p53: 32 cases; and CK5/6, EGFR, and c-Kit: 18 cases. In addition, mismatch repair protein markers MLH1, MSH2, MSH6, and PMS2 were performed in 34 cases. We found that PAX-8 expression was lost in most cases (83%). In addition, estrogen and progesterone receptors were negative in 83% and 82% of cases, respectively. Seventy-seven percent of cases were positive for keratin cocktail and keratin 8/18, whereas only 11% of cases were positive for keratin 5/6. p16 was diffusely positive in 34% of cases, whereas p53 was expressed in >75% of the tumor cells in 31% of cases. MLH1 and PMS2 were concurrently lost in 50% of cases, whereas MSH2 and MSH6 were lost in 1 case (3%). E-cadherin and CD44 were completely lost in 50% of cases, whereas Her-2/neu was negative in all cases. EGFR was negative in 67% of cases, whereas 22% of cases showed diffuse membranous staining for this marker. UCAe is a high-grade carcinoma of Müllerian origin which tends to be negative for PAX-8. The loss of this marker appears to be a more reliable discriminator than the loss of keratin expression in the differential diagnosis with endometrioid carcinoma or serous carcinoma. UCAe tends to be diffusely positive for p53, but patchy positive for p16. Although UCAe appears to share not only some histologic features with BLCB, but also some of its immunohistochemical features (loss of estrogen receptor, progesterone receptor, and Her-2/neu, a tendency to loose e-cadherin and to express CD44), UCAe appears not to be related to BLCB because it usually lacks the expression EGFR, CK5/6, and c-Kit.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26598976     DOI: 10.1097/PGP.0000000000000248

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  19 in total

1.  Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.

Authors:  Lien N Hoang; Yow-Shan Lee; Anthony N Karnezis; Basile Tessier-Cloutier; Noorah Almandani; Mackenzie Coatham; C Blake Gilks; Robert A Soslow; Colin J R Stewart; Martin Köbel; Cheng-Han Lee
Journal:  Histopathology       Date:  2016-07-05       Impact factor: 5.087

2.  Role of epithelial-mesenchymal transition factors in the histogenesis of uterine carcinomas.

Authors:  Tatiana Franceschi; Emeline Durieux; Anne Pierre Morel; Pierre de Saint Hilaire; Isabelle Ray-Coquard; Alain Puisieux; Mojgan Devouassoux-Shisheboran
Journal:  Virchows Arch       Date:  2019-02-09       Impact factor: 4.064

Review 3.  [Un- and dedifferentiated endometrial carcinoma : A rare entity with a wide range of differential diagnosis].

Authors:  A K Höhn; C E Brambs; S Opitz; R Erber; A Hartmann; L-C Horn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

Review 4.  The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future.

Authors:  Emily A Goebel; August Vidal; Xavier Matias-Guiu; C Blake Gilks
Journal:  Virchows Arch       Date:  2017-12-12       Impact factor: 4.064

Review 5.  How to approach the many faces of endometrioid carcinoma.

Authors:  Anais Malpica
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

6.  Dedifferentiated endometrial carcinoma: A report of three cases and review of the literature.

Authors:  Ryo Yokomizo; Kyosuke Yamada; Yasushi Iida; Takako Kiyokawa; Kazu Ueda; Motoaki Saito; Nozomu Yanaihara; Mayo Nakamura; Aikou Okamoto
Journal:  Mol Clin Oncol       Date:  2017-10-03

7.  Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.

Authors:  Mackenzie Coatham; Xiaodong Li; Anthony N Karnezis; Lien N Hoang; Basile Tessier-Cloutier; Bo Meng; Robert A Soslow; C Blake Gilks; David G Huntsman; Colin J R Stewart; Lynne M Postovit; Martin Köbel; Cheng-Han Lee
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

8.  Application of CT and MRI combined with VEGF-C and EGFR in the identification of endometrial cancer stages.

Authors:  Changsong Li; Jingsheng Yu; Zhexiang Fu
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

9.  Neuroendocrine Carcinoma of the Endometrium: A Clinicopathologic Study of 25 Cases.

Authors:  Cady E Pocrnich; Preetha Ramalingam; Elizabeth D Euscher; Anais Malpica
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

10.  Cytologic features of undifferentiated and dedifferentiated carcinomas of the endometrium.

Authors:  Amir-Hossein Akbari; Lu Wang; Robert A Soslow; Rajmohan Murali
Journal:  Cancer Cytopathol       Date:  2020-09-16       Impact factor: 5.284

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.